ACRS vs JAZZ · rev $3.6M vs P/E 1988, rev $2.28B
Aclaris Therapeutics Inc (ACRS) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
Aclaris Therapeutics Inc (ACRS) is a biotechnology company listed on NASDAQ.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Latest reported ACRS revenue for 2026-06-30 was $3.6M. Net income was -$41.3M. Revenue was up 81.6% from 2026-03-31 to 2026-06-30. ACRS currently screens at market cap $615.9M.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
ACRS currently screens at market cap $615.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the ACRS and JAZZ stock pages for the full models.
Not investment advice.